Bill Linder Named New CEO of HealthTronics – Experienced Executive with Proven Track Record

Bill Linder was formerly President of Development for Surgical Care Affiliates (SCA), a leader in outpatient surgical care with more than 230 ambulatory surgery centers across the U.S.

At SCA, Bill Linder held several senior operational and business development roles within executive leadership. In 2017 and 2016, he was named a Rising Star in Healthcare by Becker’s Hospital Review and Becker’s ASC Review. Prior to joining SCA, Linder held sales leadership roles with Harden Healthcare and Apria Healthcare.

“HealthTronics has established itself as a top provider of specialized mobile medical therapies and highly trained personnel to physicians and healthcare systems who utilize these solutions throughout the U.S.,” Linder said. “I look forward to working with my teammates to make HealthTronics a premier partner for the mobile medical therapies we provide and an employment destination for top talent.”

Bill Linder said his focus going forward includes strengthening HealthTronics’ partnerships with independent medical groups and healthcare systems, enhancing the patient experience through superior clinical quality, and expanding into new markets.

“In this time of COVID-19, it is particularly important that our mobile solutions are helping healthcare systems and physicians deliver specialized care in optimized settings in a cost effective manner,” said Linder.

HealthTronics‘ customers include healthcare systems, surgery centers and other medical groups looking for efficient ways to add sophisticated medical equipment while lowering their capital expenditures. HealthTronics mobile medical technology offering includes lithotripsy, lasers, ultrasound, and cryoablation systems which are maintained and managed by HealthTronics, allowing physicians and other medical providers to focus on what they do best.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”